Article on VERU talks about CytoDyn... "Well, renowned

New Post Public Reply Private Reply Replies (0) Message Board
brentie
879

Article on VERU talks about CytoDyn...

"Well, renowned COVID-19 expert, Eric Topol criticized the results in the following retweet from the New York Times. His contention seemed to be based on the size of the study. No other small biotech has gotten an EUA with such a small sample. Typically the FDA needs to see 400+ patients in a phase 3 clinical trial. Veru is far short of that and follows in the footsteps of other biotechs like CytoDyn Inc. (OTCMKTS: CYDY) which achieved 82% reduction in 14-day mortality (p=.029) in critically ill patients who took a subcutaneous injection of leronlimab. Leonlimab has a much better efficacy profile and more patients (309) than VERU’s sabizabulin, but didn’t receive an EUA. The best comparable to sabizabulin, however, is Tollovir™, manufactured by Todos Medical (OTCMKTS: TOMDF) which had a 100% reduction in mortality in severe to critical patients and reduced time of hospitalization and progression to a ventilator. For comparison purposes, the placebo group in leronlimab had a 24% mortality rate for severe to critical but they did not age stratify properly. The placebo group for Tollovid had a 22% mortality in severe to critical. In the active arm of Veru’s Sabizabulin phase 3 trial, the mortality rate was 20% for moderate-to-severe hospitalized COVID-19 patients. Discrepancies so far from the norm need to be explained. The theory that explains this discrepancy traces back to the enormous differences in case fatality by country.

The GILD, HGEN, TOMDF, and CYDY mortality data reconciles to real world conditions. The only thing that doesn’t make sense is: why the regulatory process wasn’t accelerated for any of the drugs besides Gilead’s on the announcement of such good data during a pandemic.

If we learned anything from CytoDyn’s mishaps, it was that even 309 patients isn’t necessarily enough for an EUA. Granted, CytoDyn had issues with statistical significance without post-hoc age stratification as their CRO failed to balance placebo and drug arms with respect to age, skewing results. However, the issues with Veru’s smaller trial, including not even having enough placebo patients to account for one per site, coupled with potential dissimilar standards of care (SOC) or patient management means that there probably isn’t balanced enrollment with respect to clinical sites and their standard practices. Also, the death rate in Veru’s trial is likely to raise eyebrows at the FDA if the company ever requests an EUA as a variety of other trials as well as academic literature suggest that the death rate for moderate to severe COVID-19 is not as high as 45%; it tends to track closer to 20%, especially ever since the SOC incorporated antivirals like remdesivir, and for critically ill patients, dexamethasone."

https://insiderfinancial.com/verus-nasdaq-ver...ua/183126/

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

CD Rates Offer Stillness as Stocks and Gold Wobble

Updated Category News Views 16

November has delivered the sort of tape that makes a supposedly diversified portfolio feel like a leaky boat. Stocks fell sharply, gold slid to a one-year low after record highs as recently as January, and Treasuries have not provided the dependable ballast many investors expected. When inflation worries and federal-debt concerns shove yields higher, bond prices can drop...

Continue Reading
Cracking Life Insurance Needs: John Dorsa's Insights

Updated Category News Views 150

Life Insurance: A Necessary Puzzle Life’s uncertainties have a way of putting a wrench in our plans, and nothing screams uncertainty like figuring out life insurance. But fret not! HelloNation’s got insights on this financial maze, and they’ve roped in insurance pro John Dorsa from Ridgeland to help out. Calculating Coverage Needs Forget the one-size-fits-all...

Continue Reading
CSMI Boosts CT's Cybersecurity for Defense Sector

Updated Category News Views 132

Paving the Way for Cybersecurity Excellence Out in chilly Connecticut, CSMI made a mark. The State's Office of Manufacturing picked them to join the advisory council for the Defense CyberSecure Program (CT-DCP). It ain’t just a pat on the back; it's a big deal for the region's defense and aerospace manufacturing gang. Connecticut's got its eyes set on beefing up its...

Continue Reading
Biotech Hit or Miss: Trials and Tribulations

Updated Category News Views 127

Biotech's Roller Coaster: Triumphs and Setbacks Ah, the biotech sector—it's a bit like jumping on a bull, ain't it? You barely hang on when the beast bucks. Monday's market action was downright wild. The S&P 500 didn't have a party, tumbling 1.92%, and the Nasdaq wasn't any friendlier, plummeting 2.49%. Yet, inside this storm, we see some biotech names either catching...

Continue Reading
NVCA Refreshes Key Venture Legal Documents for 2026

Updated Category News Views 115

Keeping Pace with Evolving Venture Norms Change never lets up in the fast-paced world of venture capital, does it? Just when you think you've got the rules figured out, the game shifts. This time, it's the National Venture Capital Association (NVCA) shaking things up. They've given a facelift to seven of their model legal documents, a move that reshapes the legal...

Continue Reading
GALC Launches Tender Offer on 2027 Notes Amid Debt Play

Updated Category News Views 91

Aviation Leasing Giant's Strategic Financial Move Well folks, we're staring down the barrel of a financial maneuver by Global Aircraft Leasing Co., Ltd. (GALC) that’s not just another day at the office. They've kicked off a cash tender offer for their 8.750% Senior Secured Notes due 2027, aiming to sweep up any and all outstanding ones. That's $932 million in principle...

Continue Reading
TYYY Liquidation Leaves Holders With a Tight Exit Window

Updated Category News Views 28

A fund can vanish faster than investors can read the fine print, and TYYY is doing exactly that. Exchange Traded Concepts has approved the closure and liquidation of the xETFs TSLA Daily Income ETF, with the fund expected to cease operations and distribute cash on or about November 20, 2026. This is not a debate about whether holders should love or hate Tesla. The product...

Continue Reading
Stellus PBDC's Q3: Solid Income but NAV Drops

Updated Category News Views 208

Stellus PBDC: Q3 Earnings and Strategic Moves Things are getting interesting in Houston where Stellus Private Credit BDC just laid out its financial cards for the third quarter of 2026. Now, I’ve seen my fair share of quarterly reports, but Stellus seems to have stitched a quilt of mixed results this time around. Investment Income and Portfolio Shifts First off, net...

Continue Reading
PawnMate Boosts Inventory Efficiency for Pawnshops

Updated Category News Views 213

RFID Technology: Breathing New Life into Pawnshops Let's get things rolling with the cold, hard truth that pawnshops aren't exactly what most folks expect when it comes to cutting-edge technology. But times are a-changin', and PawnMate’s RFID Inventory Module is the latest twist in this industry storyline. It's like swapping out a rusty toolbox for a brand-new set of...

Continue Reading
Fuel Cell Market Faces Uneven Growth Amid Revenue Shifts

Updated Category News Views 144

Fuel Cell Sector Eyes Mixed Results and Big Projections The fuel cell market, oh what a beast it's becoming—a story filled with ups and downs, and more forecasts than a weather station. As we stand, this sector is poised to balloon to an $18.16 billion market by 2030. That's a growth rate of 26.3% annually, folks. These projections are driving excitement, but the...

Continue Reading

Top 5 Most Recently Viewed Articles

PHX Minerals Set to Release Full-Year 2024 Financial Results

Updated Category News Views 176

PHX Minerals Reveals Upcoming Financial Results Announcement PHX MINERALS INC., commonly known as PHX, is preparing to share its financial results for the year that concluded on December 31, 2024. This announcement is eagerly awaited by investors and stakeholders, marking a significant moment in understanding the company’s financial health and future outlook. Details of...

Continue Reading
Baird Optimistic on First Industrial Realty Trust Growth Ahead

Updated Category News Views 183

Baird's Positive Outlook for First Industrial Realty Trust Baird has reaffirmed its positive stance on First Industrial Realty Trust (NYSE: FR), maintaining an Outperform rating alongside a $61.00 price target. The firm's analysis indicates that the company's core portfolio is projected to deliver a stable 6% annual growth, signaling strong performance prospects for...

Continue Reading
Aprea Therapeutics Secures $3.1 Million Investment for Growth

Updated Category News Views 151

Aprea Therapeutics Secures $3.1 Million Investment Aprea Therapeutics, Inc. (Nasdaq: APRE), a forward-thinking clinical-stage biopharmaceutical company, has announced a notable private placement aimed at enhancing its development of innovative cancer treatments. This financing comes from a blend of new and existing investors, reflecting confidence in the company’s...

Continue Reading
Silal and SVG Forge New Paths in Sustainable Agriculture

Updated Category News Views 174

Silal and SVG Forge New Paths in Sustainable Agriculture In a significant development for the agricultural sector, Silal, a leading agri-food and technology company, and Shouguang Colorful Manor Modern Agriculture Co., Ltd (SVG) have entered a joint venture that stands to revolutionize sustainable agriculture practices. This landmark agreement was witnessed by eminent...

Continue Reading